These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


202 related items for PubMed ID: 17682103

  • 1. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
    Henrichfreise B, Wiegand I, Luhmer-Becker I, Wiedemann B.
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3642-9. PubMed ID: 17682103
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.
    Cabot G, Zamorano L, Moyà B, Juan C, Navas A, Blázquez J, Oliver A.
    Antimicrob Agents Chemother; 2016 Jan 04; 60(3):1767-78. PubMed ID: 26729493
    [Abstract] [Full Text] [Related]

  • 4. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
    Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, Haussler S, Oliver A.
    Antimicrob Agents Chemother; 2014 Jun 04; 58(6):3091-9. PubMed ID: 24637685
    [Abstract] [Full Text] [Related]

  • 5. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1.
    Riera E, Macià MD, Mena A, Mulet X, Pérez JL, Ge Y, Oliver A.
    J Antimicrob Chemother; 2010 Jul 04; 65(7):1399-404. PubMed ID: 20435779
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E, Cabot G, Mulet X, García-Castillo M, del Campo R, Juan C, Cantón R, Oliver A.
    J Antimicrob Chemother; 2011 Sep 04; 66(9):2022-7. PubMed ID: 21653605
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Bactericidal activity of biapenem against various efflux system mutants of Pseudomonas aeruginosa].
    Hiraishi T, Miyata A, Takata T, Araake M, Ogawa H, Gotoh N, Nishino T.
    Jpn J Antibiot; 2002 Feb 04; 55(1):67-76. PubMed ID: 11977922
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD, Borrell N, Segura M, Gómez C, Pérez JL, Oliver A.
    Antimicrob Agents Chemother; 2006 Mar 04; 50(3):975-83. PubMed ID: 16495260
    [Abstract] [Full Text] [Related]

  • 14. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
    Kuti JL, Horowitz S, Nightingale CH, Nicolau DP.
    Pharmacotherapy; 2005 Jul 04; 25(7):935-41. PubMed ID: 16006272
    [Abstract] [Full Text] [Related]

  • 15. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
    Solé M, Fàbrega A, Cobos-Trigueros N, Zamorano L, Ferrer-Navarro M, Ballesté-Delpierre C, Reustle A, Castro P, Nicolás JM, Oliver A, Martínez JA, Vila J.
    J Antimicrob Chemother; 2015 Nov 04; 70(11):3004-13. PubMed ID: 26260130
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital.
    Hammami S, Ghozzi R, Burghoffer B, Arlet G, Redjeb S.
    Pathol Biol (Paris); 2009 Nov 04; 57(7-8):530-5. PubMed ID: 18977099
    [Abstract] [Full Text] [Related]

  • 17. OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea.
    Lee JY, Ko KS.
    Int J Antimicrob Agents; 2012 Aug 04; 40(2):168-72. PubMed ID: 22633564
    [Abstract] [Full Text] [Related]

  • 18. A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
    Evans JC, Segal H.
    Antimicrob Agents Chemother; 2007 Oct 04; 51(10):3776-7. PubMed ID: 17682099
    [No Abstract] [Full Text] [Related]

  • 19. Development of carbapenem resistance in Pseudomonas aeruginosa is associated with OprD polymorphisms, particularly the amino acid substitution at codon 170.
    Shu JC, Kuo AJ, Su LH, Liu TP, Lee MH, Su IN, Wu TL.
    J Antimicrob Chemother; 2017 Sep 01; 72(9):2489-2495. PubMed ID: 28535274
    [Abstract] [Full Text] [Related]

  • 20. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.
    Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA.
    Antimicrob Agents Chemother; 2005 Dec 01; 49(12):4920-7. PubMed ID: 16304153
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.